New cell therapy B019 takes on tough lymphoma in first human trial
NCT ID NCT06970496
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new cell therapy called B019 in 48 people with relapsed or refractory B-cell non-Hodgkin's lymphoma. The main goals are to check safety and find the right dose. Researchers will also look for early signs that the treatment shrinks tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
B019 (a cell therapy given as an intravenous infusion)
What this could lead to
If it works, this could point toward a new treatment option for people with hard-to-treat B-cell lymphoma.
What could go wrong
This is a very early, small Phase 1 trial focused on safety, not proof of effectiveness. The treatment may not work or could cause serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Jiangxi Cancer Hospital
Nanchang, China
Contact
-
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, China
Contact
-
Shanghai General Hospital
Shanghai, China
Contact
-
Sun Yat-sen University Cancer Center
Guangzhou, China
Contact
-
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, China
Contact
-
Xijing Hospital
Xi'an, China
Contact
-
Zhujiang Hospital of Southern Medical University
Guangzhou, China
Contact